Head-to-head evidence
Olodaterol vs Proventil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Olodaterol
Marketed by Boehringer Ingelheim
NCT00467740 · Phase 2 · completed
The study randomized 296 participants to placebo or one of four olodaterol doses, but the registry does not clearly report whether treatment assignment was blinded. Its primary outcome was a lung-function surrogate rather than a hard clinical outcome, and results were mixed across doses: only olodaterol 20 micrograms significantly improved trough FEV1 versus placebo at 4 weeks.
Proventil
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00577655 · Phase 3 · completed
The trial randomized 103 children to albuterol or placebo and masked participants, caregivers, investigators, and outcome assessors. Its primary measures were physiologic lung-function outcomes rather than hard clinical outcomes; the FEV1 comparison was statistically significant, while the PEF comparison was not significant at the prespecified threshold, so the findings were mixed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olodaterol's landscape · Proventil's landscape